Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom

H L Tremlett, D K Luscombe, C M Wiles

Abstract

Objectives—To survey the use of corticosteroids in multiple sclerosis as recommended by United Kingdom consultant neurologists.

Methods—A postal questionnaire covering the use of corticosteroids for acute multiple sclerosis relapse and chronic progressive multiple sclerosis with regard to frequency of use, type of corticosteroid, and dosage regime was sent to all members of the Association of British Neurologists with a United Kingdom address.

Results—Two hundred and twelve United Kingdom consultant neurologists replied to the survey (74% response rate). Eighty six per cent indicated that they prescribed corticosteroids in more than one quarter of acute multiple sclerosis relapses seen. Intravenous methylprednisolone was recommended at some time by 99% of consultant neurologists, the most popular regime being 1 g daily for 3 days (74%; 154/208). Over one half (53%; 109/206) never recommended a subsequent tapering course of oral corticosteroids; of those that did, 25% (24/96) recommended a tapering course lasting more than 1 month. Eighty eight per cent (181/206) of prescribers of intravenous methylprednisolone were able to offer the course as a day case on the ward; 7% (15/206) at an outpatient clinic; and 5% (11/206) at home. Almost three quarters of neurologists recommended oral corticosteroids for some acute relapses, although the most popular response was for occasional use only (48%; 101/212). Forty five per cent (96/211) at least occasionally recommended steroids for patients with chronic multiple sclerosis not experiencing an acute relapse.

Conclusions—Although the vast majority of consultant neurologists would prescribe intravenous methylprednisolone for acute multiple sclerosis relapse at some time, the use of corticosteroids for multiple sclerosis was otherwise variable. There seemed to be little consensus about the use of oral steroids in acute relapse, the prescribing of a tapering course of oral steroids after intravenous methylprednisolone, or the utility of steroids in chronic multiple sclerosis. Variability of prescribing recommendations probably reflects a lack of clear evidence in the face of a wide range of clinical situations, variable access, and timing of access to neurologists in the acute phase of relapse and pressure on neurologists to treat in an otherwise “hopeless” situation. Large multicentred trials are needed to consider these issues.

Keywords: multiple sclerosis; corticosteroids; survey

Corticosteroids are widely used for multiple sclerosis. An estimated 8000 to 10 000 multiple sclerosis relapses are treated with corticosteroids each year in the United Kingdom.1 Prescribing should ideally be evidenced based, although the relevant clinical trials have utilised highly selected patients perhaps not representative of the multiple sclerosis population, insensitive outcome measures, low patient numbers, and sometimes poorly matched patient groups. This survey aimed to determine the recommendations and prescribing habits of corticosteroids for multiple sclerosis by United Kingdom consultant neurologists.

Method

After piloting a two sided questionnaire, it was sent with a covering letter and freepost return envelope to all full and associate members of the Association of British Neurologists with a United Kingdom address. Most questions were of the closed type, requiring tick box answers to reduce responder burden; a Likert scale was adopted for some questions, response options being: never, occasionally (<25% of cases), sometimes (25%–50% of cases), frequently (>50% of cases), and always. The questionnaire was anonymous, although responders could add their name and address if they wished to receive a copy of the results on completion of the study. No reminders were sent.

Results

A total of 548 questionnaires were sent out, 319 were returned, 212 being from consultant neurologists. This represents 74% of consultants in March 1997 (administrator for the Association of British Neurologists, personal communication), whose responses are detailed below.
Use of corticosteroids for multiple sclerosis (MS) as recommended by consultant neurologists of the United Kingdom (n (%) )

<table>
<thead>
<tr>
<th>Question (number of valid responders/number of expected responders)</th>
<th>Always (≥ 50% of cases)</th>
<th>Frequently (25-50% of cases)</th>
<th>Occasionally (&lt; 25% of cases)</th>
<th>Never</th>
<th>Missing</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Do you recommend/prescribe corticosteroids for acute relapses of MS? (n=209/212)</td>
<td>6 (3)</td>
<td>85 (41)</td>
<td>89 (43)</td>
<td>28 (13)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>(b) How often do you recommend/prescribe intravenous methylprednisolone for acute relapses of MS? (n=212/212)</td>
<td>26 (12)</td>
<td>87 (41)</td>
<td>63 (30)</td>
<td>33 (16)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>(c) After a course of iv methylprednisolone, how often do you recommend/prescribe a tapering course of oral corticosteroids? (n=206/209)</td>
<td>20 (10)</td>
<td>17 (8)</td>
<td>12 (6)</td>
<td>48 (23)</td>
<td>109 (53)</td>
</tr>
<tr>
<td>(d) How often do you recommend oral corticosteroids as the initial treatment for MS relapse (instead of iv methylprednisolone)? (n=212/212)</td>
<td>4 (2)</td>
<td>12 (6)</td>
<td>40 (19)</td>
<td>101 (48)</td>
<td>54 (26)</td>
</tr>
<tr>
<td>(e) Do you use corticosteroids in chronic MS (not including acute relapse)? (n=211/212)</td>
<td>0 (0)</td>
<td>2 (1)</td>
<td>9 (4)</td>
<td>85 (40)</td>
<td>115 (55)</td>
</tr>
</tbody>
</table>

Note that percentages do not always add up to 100% for questions with missing responses as the valid percentages have been shown.

CORTICOSTEROIDS FOR ACUTE MULTIPLE SCLEROSIS RELAPSE

Eighty six per cent of United Kingdom consultant neurologists would prescribe corticosteroids in 25% or more cases of acute multiple sclerosis relapse. In all, more than 99% would prescribe corticosteroids for acute multiple sclerosis relapse on some occasions (table (a)). Intravenous methylprednisolone was recommended by 83% (176/211) for the treatment of a quarter or more cases of acute multiple sclerosis relapse (table (b)); 99% of neurologists would prescribe intravenous methylprednisolone on some occasions. The most popular dosage regime was 1 g daily for 3 days (74%; 154/208 of those who recommended intravenous methylprednisolone). The second most popular was 0.5 g daily for 5 days (26%; 53/208). Some recommended either course (7%; 15/208).

ORAL CORTICOSTEROID USE AFTER A PULSED COURSE OF INTRAVENOUS METHYL PREDNISOLONE

Over half (53%; 109/206) would never recommend a tapering course of oral corticosteroids after a pulsed course of intravenous methylprednisolone, whereas 10% (20/205) always would (table (c)). Oral prednisolone was recommended by 91% (87/96) and dexamethasone by 10% (10/96), although one consultant would use either. Oral prednisolone starting doses ranged from 20 to 100 mg daily, tapering to zero over 5 to 42 days. Fifty five per cent (53/96) recommended a course tapering for 2 or more weeks, and 25% (24/96) for a month or more. Of the 10% (20/206) that always recommended a tapering course of oral prednisolone, 60% (12/20) specified a course tapering for 2 or more weeks and 20% (4/20) for a month or more. Five recommended alternate daily dosing. Oral dexamethasone regimes ranged from 6 to 16 mg daily tapering to zero over 5 to 20 days, the most popular course being a starting dose of 16 mg (the equivalent anti-inflammatory dose of prednisolone being 107 mg) tapering to zero over 12 to 16 days (4/10).

ADMINISTRATION OF INTRAVENOUS METHYL PREDNISOLONE OTHER THAN AS AN INPATIENT

Of those who recommended intravenous methylprednisolone, 88% (181/206) were able to offer the course as a day case on the ward; 7% (15/206) at an outpatient clinic, and 5% (11/206) at home. Three consultant neurologists (for whom it was appropriate to answer) did not respond.

ORAL CORTICOSTEROIDS FOR ACUTE MULTIPLE SCLEROSIS RELAPSE

Seventy four per cent (157/212) would recommend oral corticosteroids instead of intravenous methylprednisolone for multiple sclerosis relapse at sometime, although the most popular response was for occasional use (48%; 101/212) (table (d)). Sixty six per cent (103/156) recommended oral prednisolone, 23% (36/156) oral methylprednisolone, 14% (22/156) oral dexamethasone, and two oral prednisone. The most often endorsed oral prednisolone regime was 60 mg daily, tapering to zero over 10 to 28 days (35/156). Other regimes ranged from starting doses of 15 mg to 500 mg tapering to zero over 3 to 56 days. Six per cent (9/156) specified a tapering course lasting more than 1 month. The most popular oral methylprednisolone regimes were 500 mg daily for 5 days (44%; 16/36) and 1 g daily for 3 days (4/36). Dosage regimes of oral dexamethasone ranged from 6 to 16 mg daily for 5 to 21 days. Some recommended either of the 2 types of corticosteroid. In all 13 did not specify a dose, three of whom wrote “variable”. One did not respond to the whole question.

CORTICOSTEROIDS FOR CHRONIC MULTIPLE SCLEROSIS (NOT INCLUDING ACUTE RELAPSE)

The majority (55%; 115/211) said that they never used corticosteroids for patients with chronic progressive multiple sclerosis who were not in acute relapse, but 45% (96/211) would do so at times and 5% (11) would do so in more than a quarter of cases (table (e)). Intravenous methylprednisolone was the most popular drug for chronic progressive multiple sclerosis (76%; 70/92 of responders), the most often used regime being 1 g daily for 3 days (30 out of 65 who specified a dose). A course of oral prednisolone was the second most popular option (34%; 31/92). Courses varied greatly, ranging from starting doses of 15 to 60 mg tapering to zero over 12 to 84 or more days. Two consultants occasionally used long term oral prednisolone (more than 3 months) and two used alternate day dosing. Other corticosteroids recommended included dexamethasone (four) oral methylprednisolone (two), and ACTH (one). Five neurologists for whom it was applicable to answer the question did not
do so, a further 28% (26/92) did not specify a dosage regime, although some recommended more than one course.

Discussion

Eighty six per cent of United Kingdom consultant neurologists would prescribe corticosteroids in a quarter or more cases of acute multiple sclerosis relapse; more than 99% would prescribe corticosteroids for acute multiple sclerosis relapse on some occasions. Therefore there was consensus that steroids should be prescribed for some relapses of multiple sclerosis, intravenous methylprednisolone being recommended in a fair proportion. No clear consensus was evident as to the type, duration, and dosage of corticosteroids or in their use for chronic multiple sclerosis. Evidence from randomised clinical trials confirms that corticosteroids are superior to placebo in accelerating recovery from relapses. The first trial in the 1960s found ACTH (not commercially available in the United Kingdom any more due to its variable and unpredictable therapeutic response) to be superior to placebo,

In two later trials intravenous methylprednisolone was found to be comparable or superior to ACTH. Intravenous methylprednisolone (15 mg/kg/daily taping to zero over 15 days (n=23),

or 500 mg daily for 5 days (n=50),

or 1 g daily for 5 days (n=35) has been shown to be more effective than placebo. High dose intravenous methylprednisolone (5750 mg total over 14 days) has been shown to be comparable with intravenous dexamethasone (n=31) (78 mg over 14 days; total equivalent anti-inflammatory dose being 390 mg methylprednisolone).

Patients in clinical trials, however, may not be representative of the population seen by neurologists in clinical practice. Reasons probably include variable access of patients with relapsing multiple sclerosis to specialist neurological services: some being seen at the height of relapse, others when the relapse has resolved or is obviously improving, and an unknown proportion of less severe episodes either being assessed by the general practitioner or not at all.

There is little evidence to advocate corticosteroids in chronic progressive multiple sclerosis, although 45% of neurologists would do so at least occasionally, perhaps unconvinced by evidence based on small numbers. Alternatively there may be pressure to offer “something” in an otherwise “hopeless” situation.

Ten per cent (20/206) of neurologists always recommended a tapering course of oral corticosteroids after intravenous methylprednisolone, with 25% (24/96) advocating a course lasting a month or more. Evidence for or against tapering oral corticosteroids after intravenous methylprednisolone is scant: increased side effects have been found without measurable beneficial effects. Furthermore, the hypothalamic-pituitary-adrenal axis recovers sufficiently after short term high dose intravenous methylprednisolone such that oral replacement therapy is not required for this reason. Thus a short tapering course of oral corticosteroids seems justified only for a few patients clearly shown to relapse when a pulsed course of intravenous methylprednisolone is stopped.

Data from two recent clinical trials have suggested equivalence between oral and intravenous corticosteroids, and although almost three quarters of neurologists recommended oral corticosteroids instead of intravenous methylprednisolone for acute multiple sclerosis relapse at sometime, only a minority (8%; 16/212) often or always did so. The most popular oral corticosteroid was prednisolone (66%; 103/156) starting at 60 mg, tapering to zero over 20 to 28 days (22%; 35/156), the regime recommended in one recent trial. Fear was expressed that the prescribing of oral rather than intravenous corticosteroids for acute multiple sclerosis relapse would lead to chronic courses of corticosteroids; however, this was not substantiated by the results seen here. Only 6% (9/156) of respondents recommended oral corticosteroids for more than one month, although it is not known whether these recommendations are adhered to in practice, especially once the patient is under general practitioner supervision. Corticosteroids given orally have several advantages over those given intravenously—namely, reduced nursing and doctor time, reduced risk of infection (associated with intravenous administration), reduced necessity to admit to hospital, and an estimated cost saving of £472 000 per year in the United Kingdom (if all multiple sclerosis relapses were treated with oral prednisolone instead of intravenous methylprednisolone).

However, most neurologists remained unconvinced that oral instead of intravenous corticosteroids should be routinely prescribed; a larger randomised multicentre trial may clarify previous findings and help to rationalise practice.

The study was carried out as part of a PhD supported by the Welsh School of Pharmacy. We thank Claire Grout for help with piloting the questionnaire and Susan Tann, administrator of the Association of British Neurologists for her help and cooperation.

Thoracocervicofacial purpura as the single manifestation of epileptic seizure

A 44 year old woman who underwent ovariectomy due to bilateral ovarian cysts at the age of 29 followed by hormone replacement therapy for several years, was admitted to hospital after a generalised grand mal seizure. The patient had no history of epilepsy. Neurological examination on admission was negative; however, purpura of the thoracocervicofacial region was seen (figure). Routine blood chemistry (platelet count on FBC) and chest radiography were normal. Cranial CT and MRI did not show any parenchymal pathology. An EEG trace was within normal limits.

Purpura was described in association with generalised seizures by Bychowski. Here we report a case of thoracocervicofacial purpura as the unique manifestation of epileptic seizure. Petechial haemorrhage of the thoracocervicofacial area has been described as an unusual consequence of epileptic seizure. Here we report a case of thoracocervicofacial purpura as the unique manifestation of epileptic seizure.

PIETRO RUBEGNI
MICHELE FIMIANI
GIOVAMBATTISTA DE ALOE
LUCIO ANDREASSI
Department of Dermatology of University of Siena, Italy

MARIO RUBEGNI
Division of Geriatrics, Azienda Ospedaliera, Siena, Italy

Correspondence to: Dr Pietro Rubegni, Istituto di Scienze Dermatologiche, Università degli Studi di Siena, Policlinico “Le Scotte”, Viale Bracci, 53100 Siena, Italy. Telephone 0039 577 585420; fax 0039 577 44238.